SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-031255
Filing Date
2023-03-10
Accepted
2023-03-10 17:01:07
Documents
12
Period of Report
2023-03-08
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm239041d1_8k.htm   iXBRL 8-K 37074
  Complete submission text file 0001104659-23-031255.txt   214394

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syn-20230308.xsd EX-101.SCH 3060
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20230308_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20230308_pre.xml EX-101.PRE 22614
6 EXTRACTED XBRL INSTANCE DOCUMENT tm239041d1_8k_htm.xml XML 3614
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 23724549
SIC: 2834 Pharmaceutical Preparations